PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Pain (non-malignant) (Tramadol hydrochloride - Pain (non-malignant))
Records returned : 18 (on 02 May 2024 at 22:28:28). Return to search results for ' Pain (non-malignant) '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.07.02
Green (see narrative)
Formulations :
- Capsules
- Modified release capsules
- Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
Modified-release preparations to be prescribed by brand
01.04.02
04.07.02
Green
Formulations :
- Linctus
- Oral solution
- Tablets
ASPH
RSCH
SASH
SABP
Primary Care
04.07.01
Green
Formulations :
- Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
RSCH - prescribe as separate components - combination is non-formulary at RSCH
04.07.02
Green
Formulations :
- Modified release capsules
- Modified release tablets
- Oral solution
- Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands
04.07.01
Green (see narrative)
Formulations :
- Effervescent tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
Fixed combinations are less preferable.
Low dose (8/500 co-codamol) not recommended.
Effervescent formulations reserved for swallowing difficulties - high sodium content and more costly.
Secondary Care - for A&E / discharge only.
04.07.02
Green (see narrative)
Formulations :
- Capsules
- Modified release tablets
- Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Important
2nd-line, for patients unable to tolerate / poor response to morphine.
Modified-release preparations to be prescribed by brand
04.07.02
Green (see narrative)
Formulations :
- Patches
ASPH
RSCH
SASH
SABP
Primary Care
Important
Prescribe by brand.
Refer to Trust / Primary Care Pharmacy advice for locally preferred brands
04.07.01
Green (see narrative)
Formulations :
- Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
Fixed combinations are less preferable.
Low dose (8/500 co-codamol) not recommended.
Secondary Care - for A&E / discharge only.
Green (see narrative)
Formulations :
- Capsules
ASPH
RSCH
SASH
SABP
Primary Care
Important
Fixed combinations are less preferable.
Low dose (8/500 co-codamol) not recommended.
Secondary Care - for A&E / discharge only.
04.07.02
Blue
Formulations :
- Modified release tablets
- Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Important
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
04.07.02
Blue
Formulations :
- Buccal/sublingual
ASPH
RSCH
SASH
SABP
Primary Care
Important
Use in patients unable to tolerate codeine / dihydrocodeine tablets or where morphine is contra-indicated
04.07.02
Red
Formulations :
- Injection
- Solution for infusion
ASPH
RSCH
SASH
SABP
Primary Care
04.07.02
Red
Formulations :
- Injection
ASPH
RSCH
SASH
SABP
Primary Care
Important
2nd-line, for patients unable to tolerate / poor response to morphine.
Modified-release preparations to be prescribed by brand
01.04.02
04.07.02
Red
Formulations :
- Injection
ASPH
RSCH
SASH
SABP
Primary Care
04.07.03
04.07.04
04.08.01
Non Formulary
Formulations :
- Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
04.07.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
04.07.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
04.07.03
04.07.04
04.08.01
Non Formulary
Formulations :
- Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients